Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix

PaperCitations, authors & open-access status

A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 66 citations, 2015 year and green oa status.

66
Citations
2015
Year
green
OA Status

Related on ScholarIQ

Wei Deng
Author
International Journal of Gynecological Cancer
Journal
PARP inhibition in cancer therapy
Topic
PARP inhibition in cancer therapy
Topic
Endometrial and Cervical Cancer Treatments
Topic
Ovarian cancer diagnosis and treatment
Topic
470M+ articles · free account